A prospective study of direct medical costs in a large cohort of consecutively enrolled patients with refractory epilepsy in Italy

Abstract

SUMMARYObjective: To evaluate direct medical costs and their predictors in patients with refractory epilepsy enrolled into the SOPHIE study (Study of Outcomes of PHarmacoresistance In Epilepsy) in Italy. Methods: Adults and children with refractory epilepsy were enrolled consecutively at 11 tertiary referral centers and followed for 18 months. At entry, all subjects underwent a structured interview and a medical examination, and were asked to keep records of diagnostic examinations, laboratory tests, specialist consultations, treatments, hospital admissions, and day-hospital days during follow-up. Study visits included assessments every 6 months of seizure frequency, health-related quality of life (Quality of Life in Epilepsy Inventory 31), medication-related adverse events (Adverse Event Profile) and mood state (Beck Depression Inventory-II). Cost items were priced by applying Italian tariffs. Cost estimates were adjusted to 2013 values. Results: Of 1,124 enrolled individuals, 1,040 completed follow-up. Average annual cost per patient was € 4,677. The highest cost was for antiepileptic drug (AED) treatment (50%), followed by hospital admissions (29% of overall costs). AED polytherapy, seizure frequency during follow-up, grade III pharmacoresistance, medical and psychiatric comorbidities, and occurrence of status epilepticus during follow-up were identified as significant predictors of higher costs. Age between 6 and 11 years, and genetic (idiopathic) generalized epilepsies were associated with the lowest costs. Costs showed prominent variation across centers, largely due to differences in the clinical characteristics of cohorts enrolled at each center and the prescribing of second-generation AEDs. Individual outliers associated with high costs related to hospital admissions had a major influence on costs in many centers. Significance: Refractory epilepsy is associated with high costs that affect individuals and society. Costs differ across centers in relation to the characteristics of patients and

Understanding the burden of idiopathic generalized epilepsy in the United States, Europe, and Brazil: An analysis from the National Health and Wellness Survey

“…Specifically, prior research for the overall adult epilepsy population has found that patients with unmanaged disease have significantly more healthcare provider visits than those with effectively controlled seizures [31]. Although the annual costs for AEDs were not collected in the current study, prior research suggests that one of the biggest components of overall direct costs is AED-related costs (children and adults, 8.2% IGE) [32].…”

Economic evaluation of deep brain stimulation compared with vagus nerve stimulation and usual care for patients with refractory epilepsy: A lifetime decision analytic model

“…In addition, the economic burden of patients with controlled epilepsy differs from that of patients with refractory epilepsy, but little is known about the specific burden for those treated with VNS or DBS. 27 , 42 , 43 Second, short‐term trial evidence was extrapolated to a lifetime time horizon. This entailed that patients were not able to transition between health states after the follow‐up time of the trial (except when patients died in the model).…”

Cost‐effectiveness analysis of epilepsy surgery in a controlled cohort of adult patients with intractable partial epilepsy: A 5‐year follow‐up study

“…Moreover, health pre‐surgical care costs of epilepsy increase with the number of comorbidities . The highest cost is for antiepileptic drugs (AEDs), which account for about 50% of the total cost according to recent Italian and Chinese studies . AEDs available in the last decades are somewhat effective but much more expensive.…”